AbbVie to Acquire Apogee for $10.9B to Snag Eczema Drug Candidate
TL;DR Summary
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, gaining control of zumilokibart, a late-stage anti-IL-13 eczema antibody that could compete with Lilly’s Ebglyss and Regeneron/Sanofi’s Dupixent. The deal complements AbbVie’s immunology portfolio (Skyrizi, Rinvoq) and may offer less frequent dosing (every 3–6 months) based on Phase 2 data. Apogee previously secured up to $1.3 billion from Blackstone Life Sciences, and the transaction values the stock at $135.11 per share. Key milestones include one-year Phase 2 data anticipated in early 2027 and Phase 3 data in 2028."
- AbbVie inks $10.9B Apogee buyout to bag eczema prospect Fierce Biotech
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ
- AbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business Daily
- Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising Barron's
- AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal The Boston Globe
Reading Insights
Total Reads
0
Unique Readers
5
Time Saved
2 min
vs 3 min read
Condensed
82%
490 → 89 words
Want the full story? Read the original article
Read on Fierce Biotech